AZ Fasenra shows benefit in chronic rhinosinusitis with nasal polyps
The drug reduced the size of nasal polyps and reduced nasal blockage
Read More
Tag: benralizumab
AZ’s Fasenra study confirms robust efficacy in eosinophilic asthma
Drug reduced annual rate of asthma exacerbations by 49%
Read More
FDA green light for Fasenra
Currently there are no FDA-approved treatments for eosinophilic oesophagitis.
Read More
AZ’ Fasenra shows long-term efficacy in eosinophilic asthma
AstraZeneca has unveiled data from a Phase III extension trial highlighting the efficacy of biologic Fasenra as an add-on maintenance treatment in patients with severe eosinophilic asthma.
Read More
NICE backs AZ’ asthma biologic Fasenra
AstraZeneca’s biologic Fasenra will likely be funded on the NHS as a treatment for people with severe eosinophilic asthma.
Read More
EU approves AZ’ biologic Fasenra for severe asthma
AstraZeneca’s biologic Fasenra has been approved for use in Europe as an add-on maintenance treatment in patients with severe eosinophilic asthma.
Read More
AZ’ Fasenra gets US nod for eosinophilic asthma
AstraZeneca’s biologic Fasenra has picked up its first global approval in the US as a treatment for severe, eosinophilic asthma, a difficult to treat form of the condition.
Read More
Ten new medicines leap towards EU approval
The European Medicines Agency’s Committee for Medicinal Products for Human Use has put 10 medicines forward for approval in the region, including new options for multiple sclerosis, eosinophilic esophagitis and eosinophilic asthma.
Read More
AZ asthma drug cuts oral steroid use
Patients with severe uncontrolled asthma taking AstraZeneca’s experimental drug benralizumab in a late-stage study either significantly reduced or stopped altogether their intake of oral corticosteroids (OCS), while the drug was also shown to dramatically cut related hospitalisations.
Read More
AZ asthma biologic cuts exacerbations, improves symptoms
The Lancet has published data from two trials of AstraZeneca’s biologic benralizumab showing that the drug significantly reduced exacerbations and improved lung function and symptoms in patients with severe eosinophilic asthma.
Read More
AZ’ benralizumab cut asthma exacerbations in PhIII trial
AstraZeneca says that its investigational respiratory biologic benralizumab has turned in another successful performance in clinical trials, significantly reducing asthma exacerbations compared to a placebo.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
